Literature DB >> 29634828

Benralizumab (Fasenra) for Severe Eosinophilic Asthma.

.   

Abstract

Entities:  

Year:  2018        PMID： 29634828     DOI： 10.1001/jama.2018.3609

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives.

Authors:  Amelia Licari; Sara Manti; Riccardo Castagnoli; Giuseppe Fabio Parisi; Carmelo Salpietro; Salvatore Leonardi; Gian Luigi Marseglia
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

2.  Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report.

Authors:  Johannes Anthon Kroes; Sander Wilhelm Zielhuis; Carina Bethlehem; Anneke Ten Brinke; Eric Nico Van Roon
Journal:  Eur J Hosp Pharm       Date:  2021-04-21

3.  Anaphylaxis to three humanized antibodies for severe asthma: a case study.

Authors:  Koichi Jingo; Norihiro Harada; Toshihiko Nishioki; Masahiro Torasawa; Tomoko Yamada; Tetsuhiko Asao; Haruhi Takagi; Tomohito Takeshige; Jun Ito; Kazuhisa Takahashi
Journal:  Allergy Asthma Clin Immunol       Date:  2020-06-10       Impact factor: 3.406

Review 4.  Asthma in Pregnancy: Pathophysiology, Diagnosis, Whole-Course Management, and Medication Safety.

Authors:  Huijie Wang; Na Li; Huaqiong Huang
Journal:  Can Respir J       Date:  2020-02-22       Impact factor: 2.409
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.